TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

JIANGSU HENGRUI MED

OncologyMetabolicGastroenterology
Pharma

JIANGSU HENGRUI MED is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology.

-
Since
0
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 75%
0 drugs Phase 3: 38 Phase 2: 33 Phase 1: 90
Metabolic 9%
0 drugs Phase 3: 5 Phase 2: 4 Phase 1: 11
Gastroenterology 7%
0 drugs Phase 3: 4 Phase 2: 3 Phase 1: 6
Immunology 5%
0 drugs Phase 3: 1 Phase 2: 4 Phase 1: 7
Cardiovascular 4%
0 drugs Phase 3: 3 Phase 1: 6

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Metabolic